Home » Stocks » ANGO

AngioDynamics, Inc. (ANGO)

Stock Price: $19.02 USD 0.19 (1.01%)
Updated Jan 27, 2021 4:00 PM EST - Market closed
Market Cap 719.41M
Revenue (ttm) 271.10M
Net Income (ttm) -171.31M
Shares Out 38.33M
EPS (ttm) -4.49
PE Ratio n/a
Forward PE 625.00
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $19.02
Previous Close $18.83
Change ($) 0.19
Change (%) 1.01%
Day's Open 18.80
Day's Range 18.40 - 19.61
Day's Volume 499,501
52-Week Range 8.26 - 19.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 2 weeks ago

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 2 weeks ago

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.

Seeking Alpha - 2 weeks ago

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research - 2 weeks ago

AngioDynamics (ANGO) delivered earnings and revenue surprises of 150.00% and 8.01%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 weeks ago

Shares of AngioDynamics (NASDAQ:ANGO) were unchanged in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 83.33% year over year to $0.01,...

Business Wire - 3 weeks ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Business Wire - 3 weeks ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Business Wire - 4 weeks ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Business Wire - 1 month ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Zacks Investment Research - 2 months ago

The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.

Business Wire - 2 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Zacks Investment Research - 2 months ago

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 3 months ago

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 3 months ago

Investor confidence is high in AngioDynamics (ANGO) stock, thanks to solid prospects.

Zacks Investment Research - 3 months ago

As of late, it has definitely been a great time to be an investor in AngioDynamics.

Zacks Investment Research - 3 months ago

AngioDynamics (ANGO) witnessed revenue growth across two business segments in fiscal Q1.

InvestorPlace - 3 months ago

AngioDynamics (ANGO) earnings for the company's fiscal first quarter of 2021 have ANGO stock on the rise Tuesday after beating estimates. The post AngioDynamics Earnings: ANGO Stock Soars 19% ...

Seeking Alpha - 3 months ago

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q1 2021 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

AngioDynamics (ANGO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Invezz - 3 months ago

AngioDynamics Inc. (NASDAQ: ANGO) reported its quarterly earnings on Tuesday before the bell. The company said its net sales jumped 6.3% in the fiscal Q1 to £54.54 million on the back of an or...

Zacks Investment Research - 3 months ago

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 6.95%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 months ago

Shares of AngioDynamics (NASDAQ:ANGO) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share fell 75.00% over the past year to $0.02, which beat the es...

Business Wire - 3 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Benzinga - 3 months ago

On Tuesday, September 29, AngioDynamics (NASDAQ: ANGO) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Zacks Investment Research - 4 months ago

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 4 months ago

AngioDynamics' (ANGO) Auryon Atherectomy System leverages breakthrough technology to deliver treatment of PAD lesions and occlusions.

Business Wire - 4 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and on...

Business Wire - 4 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.

Business Wire - 5 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.

Zacks Investment Research - 5 months ago

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Business Wire - 5 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.

Zacks Investment Research - 6 months ago

AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.

Seeking Alpha - 6 months ago

AngioDynamics' (ANGO) CEO Jim Clemmer on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

AngioDynamics (ANGO) delivered earnings and revenue surprises of -20.00% and -6.28%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 months ago

Shares of AngioDynamics (NASDAQ:ANGO) were unchanged after the company reported Q4 results.

Business Wire - 6 months ago

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.

Zacks Investment Research - 6 months ago

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.

Other stocks mentioned: ECOM, LAKE, TSLA, WST
Zacks Investment Research - 7 months ago

AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.

Zacks Investment Research - 8 months ago

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 9 months ago

AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.

Seeking Alpha - 9 months ago

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2020 Results - Earnings Call Transcript

Benzinga - 9 months ago

Shares of AngioDynamics (NASDAQ:ANGO) jumped over 7% after the company reported upbeat Q3 results.

Zacks Investment Research - 9 months ago

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 11 months ago

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

Zacks Investment Research - 1 year ago

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.

About ANGO

AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, a... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
May 27, 2004
CEO
James Clemmer
Employees
800
Stock Exchange
NASDAQ
Ticker Symbol
ANGO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AngioDynamics stock is "Buy." The 12-month stock price forecast is 21.00, which is an increase of 10.41% from the latest price.

Price Target
$21.00
(10.41% upside)
Analyst Consensus: Buy